☆ 4.7 Article

Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 34, Issue 18_suppl, Pages LBA503-LBA503

Publisher

American Society of Clinical Oncology (ASCO)

DOI: 10.1200/jco.2016.34.18_suppl.lba503

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.